Media Articles Related to Aerobid (Flunisolide Inhalation)
Big City Life May Not Be a Key Asthma Risk: U.S. Study
Source: Medscape Allergy & Clinical Immunology Headlines [2015.01.21]
The simple fact of growing up in a big city may not be a major factor in whether a child develops asthma, according to a new study that contradicts decades of public health assumptions about the so-called inner city asthma epidemic.
Reuters Health Information
Identification of new cellular pathway triggering allergic asthma response
Source: Allergy News From Medical News Today [2015.01.21]
Researchers at the University of California, San Diego School of Medicine, with collaborators in Korea and Scotland, have identified a novel signaling pathway critical to the immune response of cells...
Urban living may not be to blame for asthma epidemic
Source: Respiratory / Asthma News From Medical News Today [2015.01.21]
A new study suggests that demographic factors such as race, ethnicity and income are more significant risk factors for asthma than physical surroundings.
Inner-City Asthma Risk Overrated?
Source: MedPage Today Allergy & Immunology [2015.01.21]
(MedPage Today) -- Socioeconomics and race bigger factors than urban surroundings, study says.
'Missing heritability' in asthma not explained by rare mutations
Source: Respiratory / Asthma News From Medical News Today [2015.01.20]
Despite a strong suspected link between genetics and asthma, commonly found genetic mutations account for only a small part of the risk for developing the disease - a problem known as missing...
Published Studies Related to Aerobid (Flunisolide Inhalation)
Linear growth and bone maturation are unaffected by 1 year of therapy with inhaled flunisolide hydrofluoroalkane in prepubescent children with mild persistent asthma: a randomized, double-blind, placebo-controlled trial. [2011.10]
BACKGROUND: Inhaled corticosteroids (ICS) are the preferred long-term therapy for subjects with persistent asthma. However, concerns remain about potential effects of long-term ICS use on growth in children. OBJECTIVE: To determine the effect of 1 year of inhalation therapy with flunisolide hydrofluoroalkane (HFA) on growth velocity and bone maturation in children with mild persistent asthma... CONCLUSIONS: In this study, flunisolide HFA did not suppress growth or bone maturation at the highest approved dose for children with persistent asthma. Copyright (c) 2011 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Intranasal flunisolide treatment in patients with non-allergic rhinitis. [2011.04]
Non-allergic rhinitis (NAR) is a heterogeneous disease, characterized by nasal hyperreactivity and inflammation...
High-dose inhaled flunisolide versus budesonide in the treatment of acute asthma exacerbations in preschool-age children. [2009.04]
The role of inhaled corticosteroids in asthma exacerbation is debated. We compared high doses of nebulized budesonide versus high doses of nebulized flunisolide, in association with a short-acting beta-2-agonist, in the treatment of moderate asthma exacerbation in preschool children... High doses of inhaled flunisolide and budesonide are both effective in the management of moderate asthma exacerbations in pre-school-age children, but the flunisolide therapeutic effect was faster than budesonide.
Intranasal flunisolide treatment in children with adenoidal hypertrophy. [2007.10]
Adenoidal hypertrophy (AH) represents one of the most frequent indications for surgery in children and it has been proposed that treatment with intranasal corticosteroids can decrease the size of AH.In conclusion, this preliminary study demonstrates that an 8-week treatment with intranasal flunisolide is significantly associated with reduction of AH, thus preventing the recurrence to adenoidectomy, and is safe.
Inhaled flunisolide suppresses the hypothalamic-pituitary-adrenocortical axis, but has minimal systemic immune effects in healthy cats. [2006.01]
Feline bronchial disease is commonly treated with oral glucocorticoids (OGC), which might be contraindicated in cats with certain infectious, endocrine, renal, or cardiac diseases...
Clinical Trials Related to Aerobid (Flunisolide Inhalation)
Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q) [Completed]
The objective of this cross-over study is to validate the Preference Module of the EARNS-Q in
adult subjects (>=18 years of age) with Seasonal Allergic Rhinitis (SAR) taking
beclomethasone dipropionate and beclomethasone dipropionate and flunisolide.
Mentored Patient-Oriented Research Career Development Award [Recruiting]
Asthmatics have inflammation in the large airways (tubes through which air travels in and
out of the lungs). The large airways are located in the central lung. New research shows
that asthmatics also have inflammation in the small airways. The small airways are located
in the peripheral lung (the parts of the lung away from the central lung).
Until now, most of the inhaled medications available have been made up of big particles that
never reach the peripheral lung. The purpose of this study is to try to measure the level of
inflammation in the peripheral lung in asthmatics and see if this inflammation can be
decreased with different types of inhaled corticosteroids. The investigators will check
airway inflammation before and after use of an inhaled corticosteroid that has a large
particle size and should only reach the large airways (Flunisolide-CFC), and before and
after use of an inhaled, small particle corticosteroid that should reach both the large and
small airways (Flunisolide-HFA).
Subjects will make 6 study visits over two phases of the study. In the first phase, the
investigators will collect baseline information about subjects while they are using placebo
(inactive substance). In the second phase, subjects will take either the large or small
Visits will involve questionnaires and various tests measuring lung function (such as
spirometry, forced oscillation, and methacholine challenge). Exhaled nitric oxide will be
measured as an indication of inflammation. Subjects will also measure and make note of lung
function at home twice daily using a peak expiratory flow meter. Two of the visits will
involve fiberoptic bronchoscopy so that the investigators may collect cells and tissue
samples without surgery. Another two of the visits will involve the use of high resolution
computed tomography (HRCT) scans to indirectly evaluate disease in distant parts of the